Antibodies, viruses and vaccines

Neutralizing antibodies are crucial for vaccine-mediated protection against viral diseases. They probably act, in most cases, by blunting the infection, which is then resolved by cellular immunity. The protective effects of neutralizing antibodies can be achieved not only by neutralization of free virus particles, but also by several activities directed against infected cells. In certain instances, non-neutralizing antibodies contribute to protection. Several viruses, such as HIV, have evolved mechanisms to evade neutralizing-antibody responses, and these viruses present special challenges for vaccine design that are now being tackled.

[1]  F. Burnet,et al.  Immunological Reactions of the Filterable Viruses , 1938, Nature.

[2]  C. Janeway.  Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles. , 1945, Bulletin of the New York Academy of Medicine.

[3]  Thomas Francis,et al.  INFLUENZA: THE NEWE ACQUAYANTANCE , 1953 .

[4]  R. Good,et al.  Disturbances in gamma globulin synthesis as experiments of nature. , 1956, Pediatrics.

[5]  F. M. Davenport,et al.  PREDETERMINATION BY INFECTION AND BY VACCINATION OF ANTIBODY RESPONSE TO INFLUENZA VIRUS VACCINES , 1957, The Journal of experimental medicine.

[6]  S. Krugman.  The clinical use of gamma globulin. , 1963, The New England journal of medicine.

[7]  R. Webster,et al.  DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.

[8]  K. Lafferty,et al.  The enchancement of virus infectivity by antibody. , 1967, Virology.

[9]  R. E. Martin du Pan,et al.  Protection of nonimmune volunteers against rubella by intravenous administration of normal human gamma globulin. , 1972, The Journal of infectious diseases.

[10]  A. Notkins,et al.  Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection , 1976, Infection and immunity.

[11]  H. Balfour,et al.  Prevention or modification of varicella using zoster immune plasma. , 1977, American journal of diseases of children.

[12]  D. Strulovici,et al.  Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications. , 1979, Virologie.

[13]  R. Fujinami,et al.  Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell , 1979, Nature.

[14]  S J Leach,et al.  Original antigenic sin: experiments with a defined antigen. , 1980, Molecular immunology.

[15]  S. Halstead,et al.  Immune enhancement of viral infection. , 1982, Progress in allergy.

[16]  R. Chanock,et al.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats , 1985, Journal of virology.

[17]  S. Halstead,et al.  Profiles of antibody-dependent enhancement of dengue virus type 2 infection. , 1987, Microbial pathogenesis.

[18]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[19]  K. McCullough,et al.  Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. , 1988, Immunology.

[20]  J. Schlesinger,et al.  Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. , 1988, The Journal of general virology.

[21]  Human trials of AIDS vaccines: current status and future directions , 1989, AIDS.

[22]  T. Crawford,et al.  Antibody-mediated clearance of alphavirus infection from neurons. , 1991, Science.

[23]  M. Buchmeier,et al.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection , 1991, Journal of virology.

[24]  A. Portner,et al.  Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. , 1992, Virus research.

[25]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[26]  N. Dimmock.  Neutralization of Animal Viruses , 1993, Current Topics in Microbiology and Immunology.

[27]  D. Burton,et al.  Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. , 1993, Infectious agents and disease.

[28]  D. Burton,et al.  Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Spier.  Vaccines 93: Modern approaches to new vaccines including prevention of AIDS , 1994 .

[30]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[31]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[32]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.

[33]  G. Pantaleo,et al.  Effect of anti‐V3 antibodies on cell‐free and cell‐to‐cell human immunodeficiency virus transmission , 1995, European journal of immunology.

[34]  N. Dimmock,et al.  Update on the neutralisation of animal viruses , 1995 .

[35]  M. Mazanec,et al.  Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies , 1995, Journal of virology.

[36]  J. Schlesinger,et al.  Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. , 1995, The Journal of general virology.

[37]  Ying Sun,et al.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.

[38]  B. Murphy,et al.  Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus , 1995, Journal of virology.

[39]  H. Greenberg,et al.  Protective Effect of Rotavirus VP6-Specific IgA Monoclonal Antibodies That Lack Neutralizing Activity , 1996, Science.

[40]  R. Ahmed,et al.  Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity , 1996, Trends in Microbiology.

[41]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Zinkernagel,et al.  The influence of virus structure on antibody responses and virus serotype formation. , 1996, Immunology today.

[43]  B. Chesebro,et al.  Immunity to retroviral infection: the Friend virus model. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Tanke,et al.  Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Niels Schaft,et al.  T cell telomere length in HIV-1 infection: No evidence for increased CD4+ T cell turnover☆ , 1997 .

[46]  Bas van Steensel,et al.  Control of telomere length by the human telomeric protein TRF1 , 1997, Nature.

[47]  Q. Sattentau,et al.  HIV-1 antibody — debris or virion? , 1997, Nature Medicine.

[48]  R. Zinkernagel,et al.  Neutralizing antiviral B cell responses. , 1997, Annual review of immunology.

[49]  R. Reddel,et al.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines , 1997, Nature Medicine.

[50]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.

[51]  P. Lansdorp,et al.  Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry , 1998, Nature Biotechnology.

[52]  J. Taminiau.  Protective effect of rotavirus VP-6 specific IgA monoclonal antibodies that lack neutralizing activity. , 1998, Journal of pediatric gastroenterology and nutrition.

[53]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[54]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[55]  M. Eibl,et al.  Neutralizing Antibodies Protect against Lethal Flavivirus Challenge but Allow for the Development of Active Humoral Immunity to a Nonstructural Virus Protein , 1998, Journal of Virology.

[56]  Michael F. Good,et al.  Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge , 1998, Nature Medicine.

[57]  R. Ahmed,et al.  Long-lived plasma cells: a mechanism for maintaining persistent antibody production. , 1998, Current opinion in immunology.

[58]  Michael B. A. Oldstone,et al.  Viruses, Plagues, and History , 2020 .

[59]  C. Dupont,et al.  Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. , 1998, Immunity.

[60]  R. Siliciano,et al.  Cellular immune responses to HIV-1. , 1998, AIDS.

[61]  M. Aikawa,et al.  Immunocytochemical Colocalization of Specific Immunoglobulin A with Sendai Virus Protein in Infected Polarized Epithelium , 1998, The Journal of experimental medicine.

[62]  E. Blackburn,et al.  Ku is associated with the telomere in mammals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Brooks,et al.  Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection , 1999, Nature Medicine.

[64]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[65]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[66]  D. Burton,et al.  Human Antibody Responses to Mature and Immature Forms of Viral Envelope in Respiratory Syncytial Virus Infection: Significance for Subunit Vaccines , 1999, Journal of Virology.

[67]  J. Griffith,et al.  Mammalian Telomeres End in a Large Duplex Loop , 1999, Cell.

[68]  D. Burton,et al.  Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? , 2000, Nature Medicine.

[69]  T. von Zglinicki,et al.  Role of Oxidative Stress in Telomere Length Regulation and Replicative Senescence , 2000, Annals of the New York Academy of Sciences.

[70]  U. Dittmer,et al.  Different immunological requirements for protection against acute versus persistent Friend retrovirus infections. , 2000, Virology.

[71]  R. Zinkernagel,et al.  Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[72]  V. Maino,et al.  The CD4(+) T cell response to HIV-1. , 2000, Current opinion in immunology.

[73]  J. Shay,et al.  Transient expression of human telomerase extends the life span of normal human fibroblasts. , 2000, Biochemical and biophysical research communications.

[74]  D. Burton,et al.  Role of Antibodies in Controlling Viral Disease: Lessons from Experiments of Nature and Gene Knockouts , 2000, Journal of Virology.

[75]  R. Zinkernagel,et al.  Neutralizing antiviral antibody responses , 2001, Advances in Immunology.

[76]  P. Parren,et al.  Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[77]  W. Gerhard.  The role of the antibody response in influenza virus infection. , 2001, Current topics in microbiology and immunology.

[78]  G. Spear,et al.  The role of the complement system in virus infections. , 2001, Current topics in microbiology and immunology.

[79]  Sullivan Nj.  Antibody-mediated enhancement of viral disease. , 2001 .

[80]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[81]  J. Whitton,et al.  Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR , 2001, Nature Immunology.

[82]  Margaret A. Strong,et al.  The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability , 2001, Cell.

[83]  Kebin Liu,et al.  Cutting Edge: Telomerase Activation in Human T Lymphocytes Does Not Require Increase in Telomerase Reverse Transcriptase (hTERT) Protein But Is Associated with hTERT Phosphorylation and Nuclear Translocation , 2001, The Journal of Immunology.

[84]  R. Zinkernagel.  Maternal antibodies, childhood infections, and autoimmune diseases. , 2001, The New England journal of medicine.

[85]  N. Letvin,et al.  CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. , 2001, Current opinion in immunology.

[86]  Merck Reemerges With a Bold AIDS Vaccine Effort , 2001, Science.

[87]  P. Ogra,et al.  Vaccination Strategies for Mucosal Immune Responses , 2001, Clinical Microbiology Reviews.

[88]  P. Baumann,et al.  Pot1, the Putative Telomere End-Binding Protein in Fission Yeast and Humans , 2001, Science.

[89]  J. Mcghee,et al.  Role of mucosal antibodies in viral infections. , 2001, Current topics in microbiology and immunology.

[90]  A. Suhrbier,et al.  Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine. , 2001, AIDS research and human retroviruses.

[91]  D. Burton,et al.  The antiviral activity of antibodies in vitro and in vivo , 2001, Advances in Immunology.

[92]  E. Wherry,et al.  Vaccines: Effector and memory T-cell differentiation: implications for vaccine development , 2002, Nature Reviews Immunology.

[93]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[94]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[95]  A. McMichael,et al.  Opinion — vaccines: The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? , 2002, Nature Reviews Immunology.

[96]  D. Burton,et al.  Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody , 2002, Journal of Virology.

[97]  T. de Lange.  Protection of mammalian telomeres , 2002, Oncogene.

[98]  D. Montefiori,et al.  Prospects for vaccine protection against HIV-1 infection and AIDS. , 2002, Annual review of immunology.

[99]  Susan M. Kaech,et al.  Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. , 2002 .

[100]  Todd M. Allen,et al.  Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication , 2002, Journal of Virology.

[101]  Margaret A. Strong,et al.  Haploinsufficiency of mTR results in defects in telomere elongation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  New hope for AIDS vaccine. , 2003, Lancet.